220 results on '"Jackson, G. H."'
Search Results
2. Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs
3. Long term bone marrow culture studies of patients with lymphoid malignancies undergoing autologous bone marrow transplantation
4. Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients
5. Genetic factors influencing the risk of multiple myeloma bone disease
6. Patients in the MRC Myeloma XI trial receiving induction chemotherapy for newly diagnosed multiple myeloma containing dexamethasone at full or moderated dose have significantly reduced half-life of IgG: 259
7. Minimal residual disease predicts outcome in transplant ineligible myeloma patients: Results from the UK NCRI Myeloma XI trial: 253
8. The NCRI Myeloma XI trial for newly diagnosed symptomatic multiple myeloma (NDMM); second primary malignancy (SPM) incidence when lenalidomide is used as an induction and maintenance treatment option: 205
9. Quadruplet verus sequential triplet induction therapy approaches to maximise response for transplant eligible (TE), newly diagnosed myeloma patients (NDMM) in the NCRI Myeloma XI trial: 1
10. Science, Medicine, And The Future: Stem Cell TransplantationTopic: 76;214
11. Common variation at 12q24.13 (OAS3) influences chronic lymphocytic leukemia risk
12. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial
13. The outcome of high-dose chemotherapy and auto-SCT in patients with multiple myeloma: a UK/Ireland and European benchmarking comparative analysis
14. Variant IRF4/MUM1 associates with CD38 status and treatment-free survival in chronic lymphocytic leukaemia
15. Oestrogen receptor α gene polymorphism associates with occurrence of graft-versus-host disease and reduced survival in HLA-matched sib-allo BMT
16. Minimal residual disease is highly predictive of outcome in myeloma: results from MRC Myeloma IX: 28
17. The role of an all-oral chemotherapy containing lomustine (CCNU) in advanced,fs progressive Hodgkin lymphoma: a patient-friendly palliative option which can result in long-term disease control
18. MRC Myeloma IX: Preliminary Results from The Intensive Pathway Study: A546
19. MRD Studies in MM: Data from the MRC Myeloma IX Trial: A479
20. Serum FLC Levels Can Be Reduced Rapidly; Lower Levels Are Associated with Renal Recovery: A351
21. Prospective Study of Serum FLC and Other M-Protein Assays: When and How to Measure Response?: A346
22. British Society for Haematology, Slide session, Annual Scientific Meeting, Bournemouth, 2007
23. Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma
24. Role of interleukin-13 in predicting graft-versus-host disease; functional and genotyping studies
25. Position statement on the use of bortezomib in multiple myeloma
26. Chronic cutaneous graft-versus-host disease associated with multiple cutaneous squamous cell carcinomas
27. Human Langerhans cells in transplantation: Recipient cells survive conditioning but donor cells predominate at day 100: 125
28. An in vitro test of steroid responsiveness using a modified human skin explant model for graft-versus-host disease
29. Stem Cells – What do we do with them?
30. Strategic approach to the management of Hodgkinʼs disease incorporating salvage therapy with high-dose ifosfamide, etoposide and epirubicin: a Northern Region Lymphoma Group study (UK)
31. Acute lymphoblastic leukaemia of the L3 subtype in adults in the Northern health region of England 1983–99
32. Massive haemolysis in a group A recipient of a group O peripheral blood stem cell allogeneic transplant
33. Erythroleukaemia in the north of England: a population based study
34. Donor interleukin 1 receptor antagonist genotype associated with acute graft-versus-host disease in human leucocyte antigen-matched sibling allogeneic transplants
35. Stem cell transplantation
36. A RANDOMISED STUDY COMPARING AN ORAL REGIMEN (IDARUBICIN AND ETOPOSIDE) WITH AN (NTRAVENOUS REGIMEN (MAE) FOR CONSOLIDATION IN PATIENTS OVER 55 YEARS WITH ACUTE MYELOID LEUKAEMIA IN FIRST COMPLETE REMISSION
37. GREY-SCALE ULTRASOUND APPEARANCES OF CHRONIC PAROTID ENLARGEMENT IN ANOREXIA NERVOSA
38. TNF alpha GENE POLYMORPHISM ASSOCIATES WITH SEVERE GRAFT VERSUS HOST DISEASE IN HLA IDENTICAL SIBLING TRANSPLANTS AND CORRELATES WITH A SKIN EXPLANT MODEL FOR HUMAN GVHD
39. Fulminant encephalopathy due to the catastrophic primary antiphospholipid syndrome
40. Mutations in CRBNand other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs
41. Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial
42. Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach
43. Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control
44. Genetic factors influencing the risk of multiple myeloma bone disease
45. Stem cell transplantation
46. Autologous bone marrow transplantation in poor-risk high-grade non-Hodgkin's lymphoma in first complete remission. Newcastle and Northern Lymphoma Group
47. Stem cell transplantationTopic: 76;214
48. Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen
49. Common variation at 12q24.13 (OAS3) influences chronic lymphocytic leukemia risk
50. Stem cell transplantation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.